From January 2015, she started to practice leetcode questions; she trains herself to stay focus, develops "muscle" memory when she practices those questions one by one.
2015年初, Julia开始参与做Leetcode, 开通自己第一个博客. 刷Leet code的题目, 她看了很多的代码, 每个人那学一点, 也开通Github, 发表自己的代码, 尝试写自己的一些体会.
She learns from her favorite sports – tennis, 10,000 serves practice builds up good memory for a great serve. Just keep going.
Hard work beats talent when talent fails to work hard.
After a rough couple of years, UnitedHealth Group (NYSE:UNH) has been looking like a good buy again. The company has been stringing together some good quarters, its financials have been improving, and this year, its stock has risen 14% in value, outperforming the S&P 500. It's a stark turnaround from last year, when it was in a tailspin, with the healthcare stock declining by 35%.
On Oct. 13, the company is set to release its next round of earnings numbers for the third quarter. Another strong performance could potentially lift the stock even higher. Is it a good idea to buy it before then?
Why UnitedHealth Group stock could be heading higher
UnitedHealth Group stock has been beating the market this year, but over a five-year period, it's still in the negative, down around 10%. It's been making up for declines in recent years, but it may still have much more room to rise higher, particularly if its Q3 numbers are strong.
The stock is trading at a forward price-to-earnings multiple of just under 17, which is based on analyst expectations. It's a good value option for investors given that the average stock on the S&P 500 trades at roughly 20 times its estimated future profits.
When it last reported earnings in July, the company's numbers were better than expected, and it raised its full-year earnings guidance. Its medical benefits ratio also came in better than expectations, at 86.7%. That's a key metric, and a reduced percentage indicates better cost control and more efficient operations. It's also indicative of improving industry conditions overall. Rising costs have weighed on health insurers in recent years, but now, things look to be improving.
UnitedHealth stock may be worth buying right now
UnitedHealth's stock has been doing well, and with its low valuation, there's an incentive to buy and hold, as it can be a good value stock. Plus, given its reduced valuation, its yield is also far higher than usual, at around 2.5%. For investors, that sweetens the deal and can boost overall returns, which can be valuable in the event of a market downturn.
The healthcare company has been a good long-term investment in the past, but the last few years were an exception due to rising expenses. Now, however, with industry conditions improving and UnitedHealth in better financial shape, I believe it's safe to buy the stock again.
Should you buy stock in UnitedHealth Group right now?
Before you buy stock in UnitedHealth Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $387,158!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,365,749!*
That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.
UnitedHealth Group (UNH) ended the recent trading session at $372.80, demonstrating a -1.26% change from the preceding day's closing price. Elsewhere, the Dow saw a downswing of 0.36%, while the tech-heavy Nasdaq appreciated by 0.45%.
The stock of largest U.S. health insurer has fallen by 5.32% in the past month, lagging the Medical sector's loss of 3.65% and the S&P 500's gain of 1.27%.
UnitedHealth Group (UNH) ended the recent trading session at $372.80, demonstrating a -1.26% change from the preceding day's closing price. Elsewhere, the Dow saw a downswing of 0.36%, while the tech-heavy Nasdaq appreciated by 0.45%.
The stock of largest U.S. health insurer has fallen by 5.32% in the past month, lagging the Medical sector's loss of 3.65% and the S&P 500's gain of 1.27%.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.16% upward. Currently, UnitedHealth Group is carrying a Zacks Rank of #2 (Buy).
In terms of valuation, UnitedHealth Group is currently trading at a Forward P/E ratio of 19.02. This indicates a discount in contrast to its industry's Forward P/E of 23.21.
We can also see that UNH currently has a PEG ratio of 1.42. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Medical - HMOs industry stood at 1.42 at the close of the market yesterday.
The Medical - HMOs industry is part of the Medical sector. With its current Zacks Industry Rank of 32, this industry ranks in the top 14% of all industries, numbering over 250.
